Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
Approximately 50–60% of all patients with amyotrophic lateral sclerosis (ALS) will develop a deficit of frontotemporal function, ranging from frontotemporal dementia (FTD) to one or more deficits of neuropsychological, speech or language function which are collectively known as the frontotemporal sp...
Main Authors: | Alexander J. Moszczynski, Matthew A. Hintermayer, Michael J. Strong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fnins.2018.00259/full |
Similar Items
-
Alterations in Tau Metabolism in ALS and ALS-FTSD
by: Michael J. Strong, et al.
Published: (2020-11-01) -
Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43M337V and tauT175D protein
by: Alexander J. Moszczynski, et al.
Published: (2019-11-01) -
TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia
by: Mauro Montalbano, et al.
Published: (2020-12-01) -
Therapeutic and diagnostic challenges for frontotemporal dementia
by: Simon eD'Alton, et al.
Published: (2014-08-01) -
Genetics of frontotemporal lobar degeneration
by: Aswathy P, et al.
Published: (2010-10-01)